9Patricia AG,Kandice KM,Emilio DP,et al.Profile and prevalence of aspirin resistance in patients with cardiovascular disease [J].Am J Cardiol,2001,88:230.
10Mehta SR.Aspirin and clopidogrel in patients with ACS undergoing PCI:CURE and PCI-CURE[J].J Invasive Cardiol, 2003,15(Suppl B):17B.
二级参考文献14
1[2]Vimara M, Vurose I, Russell J, et al. Effects of fluvastatin on leukocyte endothelial cell adhesion in hypercholesterolemic on rats[J]. Arterioscler Thromb vasc Biol, 1997, 17:1521 - 1526
2[3]Li J, Zhao SP, Li XP, et al. Noninvasive detection of endothelial dysfuction in patients with essential hypertension[J]. Int J Cardiol, 1997, 61:165 - 169
3[1]PatriciaAG, Kandice KM, Emilio DP, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J]. Am J Cardiol, 2001, 88:230 - 235
4[2]Mehta SR. Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI- CURE[J] .J Invasive Cardiol, 2003,15(Suppl B): 17B - 20B
5[3]Simoons ML. Effect of glycoprotein Ⅱ b/Ⅲ a receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV- ACS randomised trial[J].Lancet, 2001, 357(9272): 1915 - 1924
6[4]De Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST- elevation myocardial infarction.Observations from the TIMI 14 trial[J]. Circulation,2000, 101(3) :239 - 243
7[5]Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein Ⅱ b/Ⅲa inhibition: the GUSTO V randomised trial[J]. Lancet, 2001, 357(9272) :1905 - 1914
8[6]Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low - molecular- weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT) - 3 PLUS randomized trial in acute myocardial infarction [J ]. Circulation, 2003, 108(2): 135 - 142
9[7]Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for STelevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23Trial[J]. Circulation, 2002, 105(14): 1642 - 1649
10[8]Simoons M, Krzeminska - Pakula M, Alonso A, et al.Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI- SK study[J].Eur Heart J, 2002, 23 (16) :1282 - 1290
